NEW YORK, May 15, 2017 /PRNewswire/ --
Pre-market today, Stock-Callers.com directs attention to Akorn Inc. (NASDAQ: AKRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Diplomat Pharmacy Inc. (NYSE: DPLO). The US is the biggest Generic Drugs market in the world. Nearly 80% of the prescriptions written in the country are for generic drugs. Register now and get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
Lake Forest, Illinois headquartered Akorn Inc.'s shares recorded a trading volume of 2.13 million shares last Friday. The stock finished the trading session 0.06% lower at $33.15. The Company's shares have gained 0.48% in the last one month, 61.79% over the previous three months, and 51.86% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 19.09% and 31.24%, respectively. Furthermore, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the US and internationally, have a Relative Strength Index (RSI) of 72.34.
On April 25th, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'. Access our complete research report on AKRX for free at: http://stock-callers.com/registration/?symbol=AKRX
On Friday, Canton, Massachusetts headquartered Collegium Pharmaceutical Inc.'s stock ended the session 2.28% higher at $9.42 with a total trading volume of 292,756 shares. The Company's shares are trading 17.75% below their 50-day moving average. Shares of the Company, which develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases, have an RSI of 41.96.
On May 10th, 2017, Collegium Pharma reported its financial results for Q1 2017. Net loss was $23.1 million; net product revenues for Xtampza ER were $2.2 million; R&D expenses were $2.1 million; and selling, general, and administrative expenses were $22.8 million for the quarter. Additionally, the Company had cash and cash equivalents of $129.6 million as of March 31st, 2017.
On May 11th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $28 a share to $25 a share. The complimentary research report on COLL can be downloaded at: http://stock-callers.com/registration/?symbol=COLL
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock ended the day 1.29% higher at $15.70 with a total trading volume of 800,179 shares. The Company's shares have gained 18.49% in the last month and 4.32% on an YTD basis. The stock is trading 11.78% and 13.82% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 63.19.
On May 10th, 2017, Momenta Pharma announced that it will webcast its presentation at two upcoming investor conferences. The Company will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17th, 2017, at 12:20 p.m. ET in Las Vegas, NV. The Company will also present at the UBS Global Healthcare Conference on Tuesday, May 23rd, 2017, at 9:00 a.m. ET in New York, NY. Register for free on Stock-Callers.com and get access to the latest PDF format report on MNTA at: http://stock-callers.com/registration/?symbol=MNTA
Shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. recorded a trading volume of 802,947 shares. The stock ended Friday's session 1.05% lower at $17.89. The Company's shares have gained 21.29% in the last month, 22.53% over the previous three months, and 41.98% since the start of this year. The stock is trading above its 50-day moving average by 16.45%. Furthermore, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 70.57.
On May 08th, 2017, Diplomat Pharmacy has completed its acquisition of WRB Communications, Inc. ("WRB"), a health care service center company based in Chantilly, Virginia. WRB will join Envoy Health Management, LLC as part of Diplomat's commercialization support services for manufacturers, biotech firms, and other service companies. Download your free research report on DPLO at: http://stock-callers.com/registration/?symbol=DPLO
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA